

**EDWARDS LIFESCIENCES CORPORATION**  
**Unaudited Consolidated Statements of Operations**

(in millions, except per share data)	Three Months Ended December 31,		Year Ended December 31,	
	2011	2010	2011	2010
Net sales	\$430.2	\$392.4	\$1,678.6	\$1,447.0
Cost of goods sold	119.6	113.5	489.8	408.3
Gross profit	310.6	278.9	1,188.8	1,038.7
Selling, general and administrative expenses	163.4	142.4	642.4	550.0
Research and development expenses	60.7	55.9	246.3	204.4
Special charges	17.6	10.5	21.6	22.7
Interest expense (income) , net	-	0.4	(0.3)	1.5
Other expense (income), net	0.3	(0.4)	(4.8)	(8.1)
Income before provision for income taxes	68.6	70.1	283.6	268.2
Provision for income taxes	5.5	5.3	46.9	50.2
Net income	\$63.1	\$64.8	\$236.7	\$218.0

**Earnings per share:**

Basic	\$0.55	\$0.57	\$2.07	\$1.92
Diluted	\$0.53	\$0.54	\$1.98	\$1.83

**Weighted-average common shares outstanding:**

Basic	114.1	114.5	114.6	113.7
Diluted	118.1	120.1	119.4	119.2

**Operating Statistics**

As a percentage of net sales:				
Gross profit	72.2%	71.1%	70.8%	71.8%
Selling, general and administrative expenses	38.0%	36.3%	38.3%	38.0%
Research and development expenses	14.1%	14.2%	14.7%	14.1%
Income before provision for income taxes	15.9%	17.9%	16.9%	18.5%
Net income	14.7%	16.5%	14.1%	15.1%
Effective tax rate	8.0%	7.6%	16.5%	18.7%

Note: Numbers may not calculate due to rounding.

**EDWARDS LIFESCIENCES CORPORATION****Unaudited Balance Sheets**

(in millions)

	<b>December 31, 2011</b>	<b>December 31, 2010</b>
<b>ASSETS</b>		
<b>Current assets</b>		
Cash and cash equivalents	\$171.2	\$396.1
Short-term investments <sup>(A)</sup>	279.3	-
Accounts and other receivables, net	320.7	302.5
Inventories, net	261.3	203.6
Deferred income taxes	43.9	32.3
Prepaid expenses	35.0	35.4
Other current assets	57.1	62.7
Total current assets	<u>1,168.5</u>	<u>1,032.6</u>
Property, plant and equipment, net	304.3	269.8
Goodwill	349.8	315.2
Other intangible assets, net	66.9	67.1
Investments in unconsolidated affiliates	21.8	25.0
Deferred income taxes	20.0	44.5
Long-term accounts receivable, net	24.6	-
Other assets	24.6	13.0
Total assets	<u><u>\$1,980.5</u></u>	<u><u>\$1,767.2</u></u>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
<b>Current liabilities</b>		
Accounts payable and accrued liabilities	\$335.2	\$296.0
Short-term debt	-	41.8
Total current liabilities	<u>335.2</u>	<u>337.8</u>
Long-term debt	150.4	-
Other long-term liabilities	157.0	121.2
<b>Stockholders' equity</b>		
Common stock	120.0	117.0
Additional paid-in capital	300.5	211.3
Retained earnings	1,360.7	1,124.0
Accumulated other comprehensive loss	(37.5)	(42.1)
Treasury stock, at cost	(405.8)	(102.0)
Total stockholders' equity	<u>1,337.9</u>	<u>1,308.2</u>
Total liabilities and stockholders' equity	<u><u>\$1,980.5</u></u>	<u><u>\$1,767.2</u></u>

(A) The short-term investments of \$279.3 million represent bank time deposits with initial maturities ranging from greater than 3 months to 7 months. These highly liquid short-term investments were presented as a component of cash and cash equivalents in error in the Company's previously reported 2011 interim unaudited condensed consolidated balance sheets. Short-term investments at March 31, 2011, June 30, 2011 and September 30, 2011 were \$108.6 million, \$292.6 million and \$207.1 million, respectively. The Company will present the purchases and sales of these short-term investments as investing activities in its Statement of Cash Flows for the full year 2011. The Company is currently evaluating the manner in which it corrects these previously reported amounts.

## EDWARDS LIFESCIENCES CORPORATION

### Non-GAAP Financial Information

To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles ("GAAP"), the Company uses non-GAAP historical financial measures. The Company uses the term "underlying" when referring to non-GAAP sales information, which excludes discontinued and newly acquired products and foreign exchange fluctuations, and "excluding special items" to also exclude gains and losses from special items such as significant investments, litigation, and business development transactions. Guidance for sales and sales growth rates is provided on an "underlying basis", and projections for diluted earnings per share, gross profit margin, selling, general and administrative expenses ("SG&A"), research and development expenses ("R&D"), effective tax rate, net income and growth is also provided on the same non-GAAP (or "excluding special items") basis due to the inherent difficulty in forecasting such items. Management does not consider the excluded items part of day-to-day business or reflective of the core operational activities of the Company as they result from transactions outside the ordinary course of business.

Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. By disclosing non-GAAP financial measures, management intends to provide investors with a more meaningful, consistent comparison of the Company's core operating results and trends for the periods presented. These non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and reflect an additional way of viewing aspects of the Company's operations that, when viewed with the Company's GAAP results, provide a more complete understanding of factors and trends affecting the Company's business. These non-GAAP measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with generally accepted accounting principles.

Non-GAAP financial measures are not prepared in accordance with GAAP; therefore, the information is not necessarily comparable to other companies. The Company is not able to provide a reconciliation of projected earnings per share, gross profit margin, SG&A, R&D, effective tax rate, net income and growth guidance, excluding special charges, to expected reported results due to the unknown effect, timing and potential significance of special charges or gains, and management's inability to forecast charges associated with future transactions and initiatives.

#### **The items described below are excluded from the GAAP financial results in the reconciliations that follow:**

**Special Charges** - The Company incurred certain special charges in 2011 and 2010 related to the following

- 1) *Worldwide realignment*: \$5.5 million charge and \$7.2 million charge in the fourth quarter of 2011 and 2010, respectively, related primarily to severance expenses associated with a global workforce realignment;
- 2) *European receivables*: \$8.8 million charge in the fourth quarter of 2011 and \$4.0 million charge in the second quarter of 2011 to reflect the increased risk associated with the Company's European sovereign debt receivables;
- 3) *Litigation settlement*: \$3.3 million charge in the fourth quarter of 2011 for a litigation settlement;
- 4) *Investment impairment*: \$3.3 million charge in the fourth quarter of 2010 and \$3.9 million charge in the third quarter of 2010 related to the impairment of certain investments in unconsolidated affiliates;
- 5) *MONARC program discontinuation*: \$8.3 million charge in the second quarter of 2010 related to the write-down of assets, primarily intellectual property, due to the discontinuation of the Company's EVOLUTION II clinical trial of the Edwards MONARC system.

Given the magnitude and unusual nature of these special charges relative to the operating results for the periods presented, these items have been excluded from non-GAAP net income and earnings per share.

**Provision for Income Taxes** - During the fourth quarter of 2011, the Company recorded a \$4.0 million tax benefit due to the expiration of various statutes of limitations. During the second and third quarters of 2011, the Company recorded a \$2.5 million and \$6.9 million tax benefit, respectively, related to a ruling made by tax authorities in Switzerland. During the fourth quarter of 2010, the Company recorded a \$7.9 million income tax benefit related to the reduction of certain intercompany pricing reserves. During the second quarter of 2010, the Company recorded a \$9.8 million income tax benefit resulting from a partial settlement of a prior year tax audit. Given the magnitude and unusual nature of the tax events relative to the periods presented, they have been excluded from non-GAAP net income and earnings per share.

**Foreign Exchange** - Fluctuation in exchange rates impacts the comparative results and sales growth rates of the Company's underlying business. Management believes that excluding the impact of foreign exchange rate fluctuations from its sales growth provides investors a more meaningful comparison to historical financial results. The impact of foreign exchange rate fluctuations has been detailed in the "Unaudited Reconciliation of Sales by Product Line and Region."

**EDWARDS LIFESCIENCES CORPORATION**  
**Reconciliation of GAAP to Non-GAAP Financial Information**

**GAAP TO NON-GAAP NET INCOME TABLE**

(in millions, except per share data)	Three Months Ended		Year Ended	
	December 31,		December 31,	
	2011	2010	2011	2010
<b>GAAP net income</b>	\$63.1	\$64.8	\$236.7	\$218.0
<b>Reconciling items:</b>				
<b>Special charges <sup>(A)</sup></b>				
1) Worldwide realignment	5.5	7.2	5.5	7.2
2) European receivables	8.8	-	12.8	-
3) Litigation settlement	3.3	-	3.3	-
4) Investment impairment	-	3.3	-	7.2
5) MONARC program discontinuation	-	-	-	8.3
<b>Total</b>	<b>17.6</b>	<b>10.5</b>	<b>21.6</b>	<b>22.7</b>
<b>Provision for income taxes</b>				
Tax effect on special charges <sup>(B)</sup>	(3.5)	(1.8)	(3.9)	(4.1)
Expiration of various statutes of limitations <sup>(A)</sup>	(4.0)	-	(4.0)	-
Resolution of outstanding transfer price issues <sup>(A)</sup>	-	(7.9)	-	(7.9)
Tax rulings and settlements <sup>(A)</sup>	-	-	(9.4)	(9.8)
<b>Total</b>	<b>(7.5)</b>	<b>(9.7)</b>	<b>(17.3)</b>	<b>(21.8)</b>
<b>Non-GAAP net income</b>	<b>\$73.2</b>	<b>\$65.6</b>	<b>\$241.0</b>	<b>\$218.9</b>

**GAAP TO NON-GAAP EARNINGS PER SHARE TABLE**

<b>GAAP earnings per share</b>	\$0.53	\$0.54	\$1.98	\$1.83
<b>Reconciling items: <sup>(C)</sup></b>				
<b>Special charges <sup>(A)</sup></b>				
1) Worldwide realignment	0.04	0.05	0.04	0.05
2) European receivables	0.07	-	0.10	-
3) Litigation settlement	0.02	-	0.02	-
4) Investment impairment	-	0.02	-	0.05
5) MONARC program discontinuation	-	-	-	0.06
<b>Total</b>	<b>0.13</b>	<b>0.07</b>	<b>0.16</b>	<b>0.16</b>
<b>Provision for income taxes</b>				
Expiration of various statutes of limitations <sup>(A)</sup>	(0.04)	-	(0.04)	
Resolution of outstanding transfer price issues <sup>(A)</sup>		(0.03)		(0.03)
Tax rulings and settlements <sup>(A)</sup>		(0.03)	(0.08)	(0.12)
<b>Non-GAAP earnings per share</b>	<b>\$0.62</b>	<b>\$0.55</b>	<b>\$2.02</b>	<b>\$1.84</b>

Note: Numbers may not calculate due to rounding.

(A) See description of "Special Charges" and "Provision for Income Taxes" on the previous page.

(B) The tax effect on non-GAAP adjustments is calculated using the relevant tax jurisdictions' statutory tax rates.

(C) All amounts are tax effected, calculated using the relevant tax jurisdictions' statutory tax rates.

**EDWARDS LIFESCIENCES CORPORATION**  
**Reconciliation of GAAP to Non-GAAP Tax Rate**

	Three Months Ended December 31, 2011	Year Ended December 31, 2011
<b>GAAP Tax Rate</b>	<b>8.0%</b>	<b>16.5%</b>
<u>Reconciling items:</u> (A)		
<b>Special charges</b>		
Worldwide realignment	0.9%	0.1%
European receivables	0.2%	(0.3%)
Litigation settlement	1.2%	0.3%
<b>Provision for income taxes</b>		
Expiration of statutes of limitations	4.8%	1.3%
Tax rulings	-	3.1%
<b>Non-GAAP Tax Rate</b>	<b>15.1%</b>	<b>21.0%</b>

(A) See description of "Special Charges" and "Provision for Income Taxes" on the Non-GAAP Financial Information page.

**EDWARDS LIFESCIENCES CORPORATION**
**Unaudited Reconciliation of Sales by Product Line and Region**

(\$ in millions)

Sales by Product Line (QTD)	4Q 2011	4Q 2010	Change	GAAP Growth Rate*
Surgical Heart Valves	\$ 163.4	\$ 160.9	\$ 2.5	1.6%
Transcatheter Heart Valves	93.2	65.3	27.9	42.7%
Total Heart Valve Therapy	256.6	226.2	30.4	13.4%
Critical Care	133.3	127.5	5.8	4.5%
Cardiac Surgery Systems	27.2	25.2	2.0	8.0%
Vascular	13.1	13.5	(0.4)	(3.2%)
<b>Total Sales</b>	<b>\$ 430.2</b>	<b>\$ 392.4</b>	<b>\$ 37.8</b>	<b>9.6%</b>

2010 Adjusted		
FX Impact	4Q 2010 Underlying Sales	Underlying Growth Rate *
\$ 2.4	\$ 163.3	0.1%
0.3	65.6	42.5%
2.7	228.9	12.5%
2.9	130.4	2.1%
0.1	25.3	7.4%
0.2	13.7	(4.7%)
<b>\$ 5.9</b>	<b>\$ 398.3</b>	<b>8.3%</b>

Sales by Product Line (YTD)	YTD 4Q 2011	YTD 4Q 2010	Change	GAAP Growth Rate*
Surgical Heart Valves	\$ 676.9	\$ 631.9	\$ 45.0	7.1%
Transcatheter Heart Valves	333.8	206.4	127.4	61.7%
Total Heart Valve Therapy	1,010.7	838.3	172.4	20.6%
Critical Care	508.3	454.1	54.2	11.9%
Cardiac Surgery Systems	107.5	100.2	7.3	7.3%
Vascular	52.1	54.4	(2.3)	(4.4%)
<b>Total Sales</b>	<b>\$ 1,678.6</b>	<b>\$ 1,447.0</b>	<b>\$ 231.6</b>	<b>16.0%</b>

2010 Adjusted		
FX Impact	YTD 4Q 2010 Underlying Sales	Underlying Growth Rate *
\$ 22.6	\$ 654.5	3.4%
11.0	217.4	53.6%
33.6	871.9	16.1%
19.4	473.5	7.3%
2.8	103.0	4.3%
2.2	56.6	(7.9%)
<b>\$ 58.0</b>	<b>\$ 1,505.0</b>	<b>11.6%</b>

Sales by Region (QTD)	4Q 2011	4Q 2010	Change	GAAP Growth Rate*
United States	\$ 154.7	\$ 144.5	\$ 10.2	7.0%
Europe	143.7	129.4	14.3	11.0%
Japan	76.8	69.6	7.2	10.5%
Rest of World	55.0	48.9	6.1	12.4%
International	275.5	247.9	27.6	11.1%
<b>Total</b>	<b>\$ 430.2</b>	<b>\$ 392.4</b>	<b>\$ 37.8</b>	<b>9.6%</b>

Sales by Region (YTD)	YTD 4Q 2011	YTD 4Q 2010	Change	GAAP Growth Rate*
United States	\$ 605.6	\$ 567.6	\$ 38.0	6.7%
Europe	574.0	457.0	117.0	25.6%
Japan	283.7	247.8	35.9	14.5%
Rest of World	215.3	174.6	40.7	23.3%
International	1,073.0	879.4	193.6	22.0%
<b>Total</b>	<b>\$ 1,678.6</b>	<b>\$ 1,447.0</b>	<b>\$ 231.6</b>	<b>16.0%</b>

\* Numbers may not calculate due to rounding